Onconic Therapeutics, a subsidiary of JEIL PHARMACEUTICAL, announced on the 7th that it received approval from the Korean Intellectual Property Office to extend the patent duration of the gastroesophageal reflux disease treatment drug "Ja Q Bo" (ingredient name: Jastaflazone) by approximately 4 years and 2 months until 2040.
This patent extension was made at the company's request regarding the manufacturing method and use of the core patent material for Ja Q Bo, extending the expiration date from July 5, 2036, to September 13, 2040.
The patent term extension registration system is a system designed to address the issue of reduced effective patent periods due to drug approval and can extend patents by up to 5 years.
An official from Onconic Therapeutics noted, "With this patent extension, Ja Q Bo can maintain its exclusive position in the domestic market until 2040," adding, "As the protection of rights for our self-developed drug has been strengthened, we plan to focus our capabilities on developing follow-up pipelines."
Ja Q Bo is a new drug for gastroesophageal reflux disease in the P-CAB (potassium-competitive acid blocker) class, with JEIL PHARMACEUTICAL researching the initial candidate substance and Onconic Therapeutics carrying out subsequent development.
It received approval from the Ministry of Food and Drug Safety in April last year and after its launch in October last year, it surpassed 10 billion won in quarterly sales based on the prescription amount in the second quarter of this year.